Cytek Biosciences, Inc. (CTKB) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2026. Cytek Biosciences, Inc. is a cell analysis solutions company leveraging Full Spectrum Profiling (FSP) technology. The company operates as a single reportable segment, manufacturing instruments and reagents in Fremont, California; Wuxi, China; and Singapore. As of July 31, 2026, there were approximately 130 million shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenue | $48.1 million | $45.6 million | $92.3 million | $87.1 million |
| Gross Profit | $28.3 million | $23.9 million | $49.6 million | $44.0 million |
| Gross Margin | 59% | 52% | 54% | 51% |
| Net Loss | $(12.2) million | $(5.6) million | $(31.0) million | $(17.0) million |
| Net Loss Per Share | $(0.09) | $(0.04) | $(0.24) | $(0.13) |
| Cash & Marketable Securities | $262.0 million (as of June 30, 2026) | |||
| Long-Term Debt | $0.2 million (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 6% year-over-year for both the quarter and the six-month period. Product revenue grew 4% (Q2) and 3% (YTD), while service revenue grew 10% (Q2) and 12% (YTD), driven by an expanding installed base.
- Gross Margin Expansion: Gross margins improved significantly (59% vs. 52% in Q2). This was primarily driven by a one-time $2.8 million reduction in cost of goods sold related to tariff refunds received in Q2 2026. Excluding these refunds, the gross margin would have been 53%.
- Operating Expenses: General and Administrative (G&A) expenses increased 24% in Q2 and 34% YTD, largely due to higher litigation-related expenses and severance costs. Research and Development (R&D) expenses increased 10% in Q2 due to higher personnel costs.
- Other Income/Expense: Other income (expense), net turned negative in 2026 compared to a gain in 2025. This was driven by a $1.6 million impairment charge on a non-marketable equity investment and increased foreign exchange losses.
- Income Taxes: The company recorded a tax provision of $0.5 million in Q2 2026 compared to a benefit of $1.2 million in Q2 2025. This shift is due to a domestic valuation allowance established in Q4 2025, which negated tax benefits from U.S. losses.
Guidance, Outlook, and Risks
- Liquidity: The company holds $262.0 million in cash and marketable securities. Management believes existing resources are sufficient to meet working capital and capital expenditure needs for at least the next 12 months.
- Legal Proceedings:
- Beckman Coulter Litigation: A patent infringement lawsuit filed by Beckman Coulter is ongoing. A trial is scheduled for August 17, 2026. The court recently granted Cytek's Daubert motions but denied summary judgment motions from both parties.
- BD Settlement: The company continues to make payments under a 2020 settlement with Becton, Dickinson and Company, with a total liability of $8.7 million recorded on the balance sheet.
- Market Risks: The company faces risks related to U.S. trade policies, including tariffs on imports from China and Singapore. While a recent Supreme Court ruling invalidated certain tariffs (leading to refunds), future trade policy changes remain uncertain. Additionally, the company is subject to U.S. export controls impacting sales to certain countries, including China.
- Operational Outlook: The company expects expenses to increase as it invests in R&D, commercial infrastructure, and global expansion. It anticipates service revenue will become an increasingly important contributor as the installed base grows.
Key Facts for Investor Verification
- Tariff Refund Impact: Verify the sustainability of the Q2 gross margin expansion, which was heavily influenced by a one-time $2.8 million tariff refund. Future margins may normalize without such adjustments.
- Investment Impairment: Confirm the details of the $1.6 million impairment on the non-marketable equity investment and assess if further impairments are likely.
- Legal Exposure: Monitor the outcome of the Beckman Coulter trial scheduled for August 2026, as an adverse ruling could result in significant damages or injunctions.
- Cash Burn Rate: While liquidity is strong ($262M), the company remains unprofitable with a net loss of $31.0 million for the first half of 2026. Investors should track the trajectory of operating cash flow, which was negative $1.4 million for the six months ended June 30, 2026.
- Export Controls: Assess the potential impact of U.S. export control restrictions on sales to China, a significant market for the company.